Subjects with an immune-active profile in the tumor microenvironment (PD-L1+, TIL+, and TMB high) or in peripheral blood (high percentage of activated CD8+ T cells and NK cells) responded favorably to JS001 treatment. The gene discussed is CD274; the disease is neoplasm.